CLINICAL CORE

临床核心

• 批准号: 7459787
• 负责人: CHARLES B SMITH
• 金额: $ 52.79万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7459787
• 关键词: Adult; African American; Age-Years; Aging; Alzheimer' s Disease; Autopsy; Biometry; Brain; Cessation of life; Characteristics; Clinic; Clinical; Clinical Data; Cognitive; Consent; Control Groups; Correlation Studies; Data; Data Set; Databases; Dementia; Development; Disease; Ensure; Evaluation; Funding; Goals; Grant; Guidelines; Image; Industry; Institution; International; Kentucky; Lewy Body Disease; Medical; Minority; Multicenter Studies; Names; Nervous System Physiology; Neurodegenerative Disorders; Neurologic; Neuropsychological Tests; Parkinson Disease; Parkinson' s Dementia; Participant; Patients; Pharmaceutical Preparations; Pilot Projects; Plasma; Population; Population Control; Program Research Project Grants; Purpose; Range; Recruitment Activity; Research; Research Personnel; Research Project Grants; Staging; Techniques; Universities; Vascular Dementia; cohort; data management; follow-up; healthy aging; innovation; mild neurocognitive impairment; neuroimaging; neuropathology; neuropsychological; normal aging; pre-clinical; research study; size; volunteer

The overall goal of the Clinical Core of the University of Kentucky Alzheimer's Disease Center (UK ADC) is to provide thoroughly evaluated, longitudinally followed, normal control subjects and Alzheimer's disease (AD) and other non-AD dementing disorders patients for innovative research studies at UK, other ADCs and institutions studying AD and aging. This Core will maintain a normal control population of 500 initially normal aged subjects who will be followed longitudinally to autopsy (all have prearranged autopsies). The major emphases will be on studies of normal aging and transition to preclinical AD, mild cognitive impairment (MCI), and early AD. Control participants will be evaluated annually with medical, neurologic, and neuropsychological tests to define subtle changes in cognitive and neurologic functions. A developmental study will be carried out to attempt to define the theoretical entity, preclinical AD, in this population. This Core will maintain a Dementia Research Clinic of 200 subjects with dementing disorders who will be followed longitudinally to autopsy (all have prearranged autopsies). Emphasis will be placed on recruiting MCI, early AD, and mixed dementia (AD/vascular dementia, AD/DLB, Parkinson's Disease Dementia) patients. Dementia Research Clinic patients undergo the same thorough annual evaluation as our control subjects. The detailed evaluation of control and dementia subjects provides a database for use by UK investigators associated with our Center and investigators at other ADCs and institutions. Longitudinally followed control subjects and MCI and early AD patients will provide important data about the course and progression of AD. The Clinical Core will expand and maintain a satellite clinic for African Americans, the Kentucky Clinic North Minority Satellite, in Lexington to provide longitudinal follow and broadening research opportunities for an understudied population. This Core will also obtain serum, plasma, buffy coats and CSF from normal control subjects, MCI and early AD patients for use by investigators. The Core will participate in the NIA AD neuroimaging initiative, NACC funded studies, ADCS trials, and industry sponsored drug trials. The uniform data set and the minimum data set are collected by this Core and submitted to NACC in a timely fashion by the Biostatistics and Data Management Core. The close relationship between the Clinical Core and the Neuropathology Core allows for unique clinical-pathological correlation studies on longitudinally followed subjects to better understand normal aging and transition to MCI and AD.

肯塔基大学阿尔茨海默氏病中心（英国ADC）临床核心的总体目标 是为了提供彻底评估的，纵向遵循的，正常的对照受试者和阿尔茨海默氏病 （AD）和其他非AD痴呆障碍患者在英国，其他ADC和 研究广告和老化的机构。 该核心将维持正常对照人群，最初是正常老年受试者 跟随尸检（都有预先尸检）。主要重点是研究 正常衰老和向临床前AD，轻度认知障碍（MCI）和早期AD的过渡。控制 参与者将每年通过医学，神经系统和神经心理学测试进行评估以定义 认知和神经系统功能的细微变化。将进行一项发展研究以尝试 在该人群中定义理论实体，临床前AD。 该核心将维持200名患有痴呆症患者的痴呆症研究诊所 跟随尸检（都有预先尸检）。重点将放在招聘上 MCI，AD和混合痴呆症（AD/血管痴呆，AD/DLB，帕金森氏病痴呆症） 患者。痴呆症研究诊所患者与我们的控制进行了相同的年度评估 主题。对控制和痴呆症受试者的详细评估提供了一个数据库，以供英国使用 与我们的中心和其他ADC和机构的调查人员相关的研究人员。纵向 遵循对照对象，MCI和早期的AD患者将提供有关该课程和的重要数据 AD的进展。 临床核心将扩大和维护肯塔基州诊所的非裔美国人的卫星诊所 列克星敦的北少数民族卫星，以提供纵向跟随并扩大研究机会 一个研究的人口。 该核心还将从正常对照受试者，MCI和 早期的AD患者被调查人员使用。核心将参加NIA AD神经影像学计划， NACC资助的研究，ADC试验和行业赞助的药物试验。统一数据集和 最低数据集由该核心收集，并通过生物统计学及时提交NACC 和数据管理核心。临床核心与神经病理学之间的密切关系 核心允许对纵向遵循受试者的唯一临床病理相关研究，以更好地 了解正常的衰老和向MCI和AD的过渡。